Pharmaceutical Pipeline
Yale is committed to advancing healthcare through groundbreaking technologies and discoveries. Explore a diverse array of pioneering projects that span the entire drug development process, from early-stage research to clinical trials. With a focus on addressing critical medical challenges, Yale's Pharmaceutical Pipeline showcases the collective expertise and dedication of our researchers who are aiming to bring tangible solutions to market for patients worldwide.
Device Diagnostic
Preclinical
Troxatyl
- Beijing HebaBiz
RIG-101
- RIGImmune
- Oncology
Mucosal covid vaccine
- Xanadu Bio
EGFR-Her2 vaccine
- Therajan
Phase I
ARV-102
ARV-102: Oral PROTAC LRRK2 degrader.
Feb 11, 2025 - Initiated a Phase 1 trial with ARV-102 in patients with Parkinson’s disease and announced Phase 1 data in healthy volunteers has been accepted for oral presentation at Alzheimer’s Disease/Parkinson’s Disease congress. Full annoucement: https://ir.arvinas.com/news-releases/news-release-details/arvinas-reports-fourth-quarter-and-full-year-2024-financial
- Dementia/Neurodegeneration
PTX-100
- Prescient
BHV-1300
Molecular Degraders of Extracellular Proteins (“MoDE™”) are bispecific molecules that target pathologic circulating proteins and direct them to the liver (or other organ systems) for degradation by the endosomal/lysosomal pathway---a novel, competitive platform with a differentiated profile relative to FcRN inhibitors. Specifically, high circulating levels of antibodies (monoclonal or polyclonal gammopathy) drive conditions such as myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus, pemphigus vulgaris, and many other diseases.
- Discovery Platform
- Inflammatory
- Therapeutics
BCSZ110
- Dynamicure
Phase II
HLD-0915
Halda Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating HLD-0915 in Metastatic Castration-Resistant Prostate Cancer
First-in-human clinical trial to evaluate safety and tolerability of a new class of small molecule medicines for the treatment of cancer, RIPTAC™ therapeutics
- Oncology
ARV-110
- Arvinas
Prostate Cancer
- Oncology
Phase III
ARV-471
- Arvinas
- Breast Cancer
INZ-701 - ENPPI Deficiency
Our lead candidate, INZ-701, is in clinical development for the potential treatment of ENPP1 Deficiency and ABCC6 Deficiency, which are driven by low levels of inorganic pyrophosphate (PPi) andadenosine. Currently, there are no therapeutic options for patients suffering from ENPP1 Deficiency and ABCC6 Deficiency – two rare disorders. We are pioneering the development of effective therapies for these patients and their families.